San Diego Business Journal


Recent and archived news stories on: Biotechnology, Doctors, Drugs, Health Insurance, HMO's/PPO's, Hospitals, Medical Devices, Nursing...
Tease photo

Reuben Shaw Tapped to Lead Salk Cancer Center

The Salk Institute announced that Reuben Shaw has been appointed director of the Salk Cancer Center.

Otonomy Inc. Announces $100 Million Public Offering of Common Stock

San Diego drug developer Otonomy Inc. announced Tuesday that it has commenced a $100 million public offering of its common stock.

NuVasive Inc. to Acquire Ellipse Technologies in $410 Million Deal

San Diego medical device maker NuVasive Inc. announced Tuesday that it will acquire Aliso Viejo-based Ellipse Technologies Inc. in a deal worth $410 million.

Pathway Genomics, GlySens Announce Funding

Two San Diego life science firms announced funding Tuesday: Pathway Genomics Corp. pulled in $40 million in a Series E round and GlySens Inc. raised $20 million in a Series D round.

Ionis Pharmaceuticals Granted Orphan Drug Designation for Huntington's Disease Drug

Ionis Pharmaceuticals, formerly Isis Pharmaceuticals, announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to IONIS-HTTRx for the treatment of patients with Huntington’s disease.

AntiCancer Inc. Developing New Method of Hair Transplantation

San Diego-based AntiCancer Inc. announced Monday it is developing a new approach to hair transplantation using cryopreserved hair follicles.

Halozyme Announces $150 Million Credit Agreement to Fund Phase 3 Study

Halozyme Therapeutics Inc. announced Monday that it has entered into a $150 million credit agreement to fund the start of its Phase 3 study in pancreatic cancer.

Inception IBD Inc. Raises $6.9M in Equity Financing

San Diego-based Inception IBD Inc. has raised $6.9 million in equity financing, according to a recent form filed with the Securities and Exchange Commission.

Ansun Biopharma Raises $4M in Equity Financing

Ansun Biopharma Inc., formerly known as NexBio Inc., has raised $4 million in equity financing, according to a recent form filed with the Securities and Exchange Commission.

Pathway Genomics Agrees to Pay More Than $4 Million to Settle Federal Allegations

Pathway Genomics Corp. has paid more than $4 million to resolve allegations that it violated the federal False Claims Act by paying kickbacks to doctors in exchange for patient referrals, the U.S. Attorney’s Office announced Wednesday.

Tease photo

S.D. Called Tops for Creating Tools for Use in Genomics

BIOTECH: S.D. to Be Leader in Confluence Of Big Data and Biology

The San Diego region is a long-established hub for genomics, with global leaders in the field calling it home. The city was referred to as the “genomics capital of the world” by former President Bill Clinton, and San Diego’s strong reputation in the field recently led to a special invitation to industry leaders to attend the White House unveiling of President Barack Obama’s Precision Medicine Initiative.

Tease photo

Life Sciences Continue to Succeed With Early Stage Activity

BIOTECH: S.D. Has Right Assets in Workforce, Research Base and VC

The life science industries are continuing to see sustained growth in San Diego County, landing the region alongside powerhouse biotech metros such as Boston, San Francisco and the Research Triangle in North Carolina. The steady rise up the ranks is attributed to the San Diego region’s expertise in early, discovery stage research, experts say.

Tease photo

Digital Health Thrives on Key Players Being in Close Proximity

WIRELESS: Biotech, Tech and Health Care Come Together Successfully

The convergence of high-tech and biotech is creating an explosion of opportunities in digital health, and San Diego is well-positioned for a competitive edge.

SeaSpine Signs Three-Year, $30 Million Credit Facility with Wells Fargo

Carlsbad-based SeaSpine Holdings Corp. (Nasdaq:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced that it has signed a three-year credit facility with Wells Fargo Capital Finance, with the option to extend for a fourth year, according to a company press release.

Batu Biologics Names Thomas Ichim Chief Scientific Officer

Batu Biologics Inc., a biotechnology company developing a cancer vaccine that targets a tumor's blood vessels, announced that Thomas Ichim has joined the company as chief scientific officer.